SECsense Logo

AstraZeneca PLC Share Awards Report: March 2025 Insights

$AZN
Form 6-K
Filed on: 2025-03-05
Source
AstraZeneca PLC Share Awards Report: March 2025 Insights

Key Information Extracted from the Financial Report (Form 6-K)

Company Information:

  • Company Name: AstraZeneca PLC
  • Commission File Number: 001-11960
  • Headquarters Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom

Reporting Period:

  • Report Date: 5 March 2025
  • Reporting Month: March 2025

Share Awards Granted:

  • On 4 March 2025, certain Persons Discharging Managerial Responsibilities (PDMRs) were granted awards of the Company's ordinary shares under two plans:
  • AstraZeneca Deferred Bonus Plan (AZDBP)
  • AstraZeneca Performance Share Plan (AZPSP)

Details of Share Awards:

  1. Pascal Soriot (CEO)
  • Shares Granted under AZDBP: 14,623
  • Shares Granted under AZPSP: 109,781
  • Award Price per Share: £119.63
  1. Aradhana Sarin (CFO)
  • Shares Granted under AZDBP: 6,243
  • Shares Granted under AZPSP: 45,494
  • Award Price per Share: £119.63

Plan Details:

  • AZDBP:
  • Represents a portion of the annual bonus for 2024 required to be deferred into shares.
  • Subject to a three-year holding period (vesting on the third anniversary of grant).
  • AZPSP:
  • Subject to performance measures focused on scientific, commercial, financial, and sustainability performance.
  • Assessment period from 1 January 2025 to 31 December 2027.
  • Shares are subject to a two-year holding period following the performance period (vesting on the fifth anniversary of grant).

Transaction Details:

  • Nature of Transactions: Grants of share awards under the AZDBP and AZPSP.
  • Date of Transactions: 4 March 2025
  • Place of Transactions: Outside a trading venue.

Regulatory Compliance:

  • The notification was made in accordance with the EU Market Abuse Regulation as part of UK law.

Corporate Overview:

  • AstraZeneca is a global biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, particularly in Oncology, Rare Diseases, and BioPharmaceuticals. The company operates in over 125 countries.

Insights:

  • The share awards reflect AstraZeneca's commitment to aligning executive compensation with performance and shareholder interests.
  • The granted shares under both plans are significant in volume, indicating confidence in future performance and growth potential.
  • The performance measures for AZPSP suggest a strategy focused on long-term sustainability and operational excellence, which may appeal to investors interested in responsible corporate governance practices.